Terms ending in 2035
Every in-force patent on Cellectis's record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,778,993 | New Repeat Variable Diresidues for Targeting Nucleotides In force · High confidence | Cellectis, S.A. | In force | High confidence | |
| US 10,196,608 | Method for in Situ Inhibition of Regulatory T Cells In force · High confidence | Cellectis | In force | High confidence | |
| US 12,252,699 | Method for Generating T-Cells Compatible for Allogenic Transplantation In force · High confidence | Cellectis | In force | High confidence | |
| US 10,357,515 | Method for Generating Batches of Allogeneic T-Cells with Averaged Potency In force · High confidence | Cellectis | In force | High confidence | |
| US 9,944,709 | CD123 Specific Chimeric Antigen Receptors for Cancer Immunotherapy In force · High confidence | Cellectis | In force | High confidence | |
| US 9,944,702 | CD33 Specific Chimeric Antigen Receptors for Cancer Immunotherapy In force · High confidence | Cellectis | In force | High confidence | |
| US 10,765,728 | Method for Generating Immune Cells Resistant to Arginine And/Or Tryptophan Depleted Microenvironment In force · High confidence | Cellectis | In force | High confidence | |
| US 10,316,101 | Bcma (CD269) Specific Chimeric Antigen Receptors for Cancer Immunotherapy In force · High confidence | Cellectis | In force | High confidence | |
| US 11,498,971 | Bcma (CD269) Specific Chimeric Antigen Receptors for Cancer Immunotherapy In force · High confidence | Cellectis | In force | High confidence | |
| US 10,378,007 | Methods for Modulating Tal Specificity In force · High confidence | Cellectis, S.A. | In force | High confidence | |
| 4 more term ends in 2035 · Pro | |||||
10 of 14 patents shown. Soonest term end first, then patent number.
Pro members see all 14.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.